Cited by 1,059Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchCancer Genomics and Diagnostics

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

Open access

Turke, Alexa B., Zejnullahu, Kreshnik, Wu, Yi-Long, Song, Youngchul, Dias-Santagata, Dora, Lifshits, Eugene, Toschi, Luca, Rogers, Andrew, Mok, Tony, Sequist, Lecia, Lindeman, Neal I., Murphy, Carly, Akhavanfard, Sara, Yeap, Beow Y., Xiao, Yun, Capelletti, Marzia, Iafrate, A. John, Lee, Charles, Christensen, James G., Engelman, Jeffrey A., Jänne, Pasi A.·2010·Cancer Cell

DOI 10.1016/j.ccr.2009.11.022PMC PMC2980857

Open this paper in CoChat — free account Open PDF

Abstract

MET amplification activates ERBB3/PI3K/AKT signaling in EGFR mutant lung cancers and causes resistance to EGFR kinase inhibitors. We demonstrate that MET activation by its ligand, HGF, also induces drug resistance, but through GAB1 signaling. Using high-throughput FISH analyses in both cell lines and in patients with lung cancer, we identify subpopulations of cells with MET amplification prior to drug exposure. Surprisingly, HGF accelerates the development of MET amplification both in vitro and in vivo. EGFR kinase inhibitor resistance, due to either MET amplification or autocrine HGF production, was cured in vivo by combined EGFR and MET inhibition. These findings highlight the potential to prospectively identify treatment naive, patients with EGFR-mutant lung cancer who will benefit from initial combination therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2009.11.022

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citation
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citation
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 2×
“Secondary mutations in EGFR itself, including the EGFR T790M ‘‘gatekeeper’’ mutation is observed in 50% of resistance cases, and amplification of the MET oncogene is observed in 20% of resistance cases (Balak et al., 2006; Bean et al., 2007; Engelman et al., 2007b; Kobayashi et al., 2005; Kosaka et al., 2006; Pao et a…”
Background
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · cited 2×
“To date, resistance mechanisms have predominately involved secondary genomic alterations in the target kinase that alter either the physical (such as steric hindrance) or biochemical (change in ATP affinity) properties of the receptor and result in drug resistance (Gorre et al., 2001; Shah et al., 2002; Yun et al., 20…”
Background
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800668 · Cited by 1,617
Self-citation

Flagged first, then by citations

Show all 37 references

Sorted by citations

Items 601–700 of 1,000

Genomic analyses to select patients for adjuvant chemotherapy: trials and tribulations
Weigelt, B., Reis-Filho, J. S., & Swanton, C. (2012) · Annals of Oncology · doi:10.1093/annonc/mds323 · Cited by 24
Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer
Lee, K., Kim, D., Yoon, S., Lee, K. H., & Kim, S. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.052 · Cited by 25
Intra-Tumor Heterogeneity Revealed by Mass Spectrometry Imaging Is Associated with the Prognosis of Breast Cancer
Gawin, M., Kurczyk, A., Niemiec, J. A., Stanek‐Widera, A., Grela-Wojewoda, A., Adamczyk, A., Biskup-Frużyńska, M., Polańska, J., & Widłak, P. (2021) · Cancers · doi:10.3390/cancers13174349 · Cited by 24
The prospect of combination therapies with the third-generation EGFR-TKIs to overcome the resistance in NSCLC
Li, S., Zhu, S., Wei, H., Zhu, P., Jiao, Y., Yi, M., Gong, J., Zheng, K., & Zhang, L. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113959 · Cited by 26
Molecular Testing in Lung Cancer: The Time Is Now
Cheng, H., Xu, X., Costa, D. B., Powell, C. A., & Halmos, B. (2010) · Current Oncology Reports · doi:10.1007/s11912-010-0118-z · Cited by 24
FGFR2 Assessment in Gastric Cancer Using Quantitative Real-Time Polymerase Chain Reaction, Fluorescent In Situ Hybridization, and Immunohistochemistry
Park, Y. S., Na, Y.-S., Ryu, M., Lee, C., Park, H. J., Lee, J., Park, S. R., Ryoo, B., & Kang, Y. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcpnflsmwwpp8dr · Cited by 24
Self-citation
JNK Pathway Activation Modulates Acquired Resistance to EGFR/HER2–Targeted Therapies
Manole, S., Richards, E. J., & Meyer, A. S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0123 · Cited by 25
Optimising translational oncology in clinical practice: Strategies to accelerate progress in drug development
Stahel, R. A., Bogaerts, J., Ciardiello, F., Ruysscher, D. D., Dubsky, P. C., Ducreux, M. P., Finn, S. P., Laurent‐Puig, P., Peters, S., Piccart, M. J., et al. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.12.004 · Cited by 22
The Current State of Molecularly Targeted Drugs Targeting HGF/Met
Yano, S., & Nakagawa, T. (2013) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyt188 · Cited by 23
The Met tyrosine kinase receptor as a therapeutic target and a potential cancer stem cell factor responsible for therapy resistance
Miękus, K. (2016) · Oncology Reports · doi:10.3892/or.2016.5297 · Cited by 23
Heterogeneity of Colorectal Cancer Progression: Molecular Gas and Brakes
Gaiani, F., Marchesi, F., Negri, F., Greco, L., Malesci, A., de’Angelis, G. L., & Laghi, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105246 · Cited by 24
Find the path of least resistance: Adaptive therapy to delay treatment failure and improve outcomes
Gedye, C. A., & Navani, V. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188681 · Cited by 23
Bioinformatically Expanded Next-Generation Sequencing Analysis Optimizes Identification of Therapeutically Relevant MET Copy Number Alterations in >50,000 Tumors
Solomon, J. P., Yang, S., Choudhury, N. J., Ptashkin, R. N., Eslamdoost, N., Falcon, C. J., Martin, A. S., Plodkowski, A. J., Wilhelm, C., Shen, R., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1321 · Cited by 23
Molecular mechanisms underlying the regulation of tumour suppressor genes in lung cancer
Jy, L., Bhandare, R. R., Boddu, S. H. S., SHAIK, A. B., Saktivel, L. P., Gupta, G., Negi, P., Barakat, M. M., Singh, S. K., Dua, K., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116275 · Cited by 25
Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients
Liu, L. L., Li, F., Pao, W. J., & Michor, F. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141665 · Cited by 23
Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions
Chuang, J. C., Salahudeen, A. A., & Wakelee, H. A. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1162786 · Cited by 23
Dual transcript and protein quantification in a massive single cell array
Park, S.-M., Lee, J. Y., Hong, S., Lee, S. H., Dimov, I. K., Lee, H., Suh, S., Pan, Q., Li, K., Wu, A. M., et al. (2016) · Lab on a Chip · doi:10.1039/c6lc00762g · Cited by 23
Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses
van Veggel, B. A. M. H., de Langen, A. J., Hashemi, S. M. S., Monkhorst, K., Rosenberg, E. H., Heideman, D. A. M., Radonic, T. R., & Smit, E. F. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.07.030 · Cited by 23
Applications of liquid biopsy in lung cancer-diagnosis, prognosis prediction, and disease monitoring.
Luo, W., Rao, M., Qu, J., & Luo, D. (2018) · Europe PMC (PubMed Central) · Cited by 23
Case History
Cui, J. J., McTigue, M. A., Kania, R. S., & Edwards, M. P. (2013) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-417150-3.00025-9 · Cited by 23
Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutationsPreprint
Brammeld, J. S., Petljak, M., Martincorena, I., Williams, S. P., García‐Alonso, L., Dalmases, A., Bellosillo, B., Robles‐Espinoza, C. D., Price, S., Barthorpe, S., et al. (2017) · Genome Research · doi:10.1101/gr.213546.116 · Cited by 23
DNA Amplifications in Breast Cancer: Genotypic–Phenotypic Correlations
Shiu, K., Natrajan, R., Geyer, F. C., Ashworth, A., & Reis-Filho, J. S. (2010) · Future Oncology · doi:10.2217/fon.10.56 · Cited by 22
SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations
Pudelko, L., Jaehrling, F., Reusch, C., Viteri, S., Stroh, C., Linde, N., Sanderson, M. P., Musch, D., Jorand‐Lebrun, C., Keil, M., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101832 · Cited by 22
Serial monitoring of genomic alterations in circulating tumor cells of ER‐positive/HER2‐negative advanced breast cancer: feasibility of precision oncology biomarker detection
Cani, A. K., Dolce, E. M., Darga, E. P., Hu, K. S., Liu, C., Pierce, J., Bradbury, K., Kilgour, E., Aung, K., Schiavon, G., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13150 · Cited by 21
Targeting the MET pathway for potential treatment of NSCLC
Li, A., Gao, H., & Wu, Y.-L. L. C. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.995093 · Cited by 22
Self-citation
Ockham’s razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancer
Stella, G. M., Gentile, A., Balderacchi, A. M., Meloni, F., Milan, M., & Benvenuti, S. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1008-4 · Cited by 22
From Chemotherapy to Combined Targeted Therapeutics: In Vitro and in Vivo Models to Decipher Intra-tumor Heterogeneity
Gambara, G., Gaebler, M., Keilholz, U., Regenbrecht, C. R. A., & Silvestri, A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00077 · Cited by 23
Supplementary Materials and Methods
Groenendijk, F. H., Zwart, W. T., Floore, A. N., Akbari, S., & Bernards, R. (2013) · Cited by 22
Metabolic Remodelling: An Accomplice for New Therapeutic Strategies to Fight Lung Cancer
Mendes, C., & Serpa, J. (2019) · Antioxidants · doi:10.3390/antiox8120603 · Cited by 21
Coexpression of receptor tyrosine kinase AXL and EGFR in human primary lung adenocarcinomas
Wu, Z., Bai, F., Fan, L., Pang, W., Han, R., Wang, J., Liu, Y., Xia, Y., Duan, H., & Xing, L. (2015) · Human Pathology · doi:10.1016/j.humpath.2015.08.014 · Cited by 21
Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS
Liu, J., Xie, L., Cheng, L., Qian, X., Liu, B., Hu, J. Y., Ren, W., & Yang, M. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s86966 · Cited by 21
Proteogenomic studies on cancer drug resistance: towards biomarker discovery and target identification
Fu, S., Liu, X., Luo, M., Xie, K., Nice, E. C., Zhang, H., & Huang, C. (2017) · Expert Review of Proteomics · doi:10.1080/14789450.2017.1299006 · Cited by 22
Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer
Facchinetti, F., Proto, C., Minari, R., Garassino, M. C., & Tiseo, M. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_16 · Cited by 22
Farnesyltransferase inhibition overcomes oncogene-addicted non-small cell lung cancer adaptive resistance to targeted therapies
Figarol, S., Delahaye, C., Gence, R., Doussine, A., Cerapio, J., Brachais, M., Tardy, C., Béry, N., Asslan, R., Colinge, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49360-4 · Cited by 26
3,6,2′,4′,5′-Pentahydroxyflavone, an Orally Bioavailable Multiple Protein Kinase Inhibitor, Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer
Sheng, Y., Li, W., Zhu, F., Liu, K., Chen, H., Yao, K., Reddy, K., Lim, D. Y., Oi, N., Li, H., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.593475 · Cited by 21
Resistance to targeted cancer drugs through hepatocyte growth factor signaling
Heynen, G. J. J. E., Fonfara, A., & Bernards, R. (2014) · Cell Cycle · doi:10.4161/15384101.2014.988033 · Cited by 21
Copy number gain of PIK3CA and MET is associated with poor prognosis in head and neck squamous cell carcinoma
Brauswetter, D., Dános, K., Gurbi, B., Félegyházi, É. F., Birtalan, E., Meggyesházi, N., Krenács, T., Tamás, L. T., & Peták, I. (2016) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-016-1905-1 · Cited by 21
Cancer as a moving target: understanding the composition and rebound growth kinetics of recurrent tumors
Foo, J., Leder, K., & Mumenthaler, S. M. (2012) · Evolutionary Applications · doi:10.1111/eva.12019 · Cited by 19
Systematic Review and Network Meta-Analysis of First-Line Therapy for Advanced EGFR -Positive Non-Small-Cell Lung Cancer
Franek, J. A., Cappelleri, J. C., Larkin-Kaiser, K. A., Wilner, K. D., & Sandin, R. (2019) · Future Oncology · doi:10.2217/fon-2019-0270 · Cited by 20
Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer
Zhao, Y., Wang, S., Yang, Z., Dong, Y., Wang, Y., Zhang, L., Hu, H., & Han, B. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.665484 · Cited by 20
A Therapeutic Target for Smoking-Associated Lung Cancer
Turner, N. C., & Seckl, M. J. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001942 · Cited by 20
Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma
He, Y., Wang, Y., Boyle, T. A., Ren, S., Chan, D., Rivard, C. J., Li, X., Li, J., Zhou, C., & Hirsch, F. R. (2016) · Medical Science Monitor · doi:10.12659/msm.896607 · Cited by 20
Evolutionary Strategy for Systemic Therapy of Metastatic Breast Cancer: Balancing Response with Suppression of Resistance
Kam, Y., Das, T., Minton, S. E., & Gatenby, R. A. (2014) · Women s Health · doi:10.2217/whe.14.23 · Cited by 20
From genomic landscapes to personalized cancer management—is there a roadmap?
Swanton, C., & Caldas, C. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05776.x · Cited by 19
Engineered Bifunctional Proteins for Targeted Cancer Therapy: Prospects and Challenges
Du, Y., & Xu, J. (2021) · Advanced Materials · doi:10.1002/adma.202103114 · Cited by 19
New Directions and Challenges in Targeted Therapies of Advanced Bladder Cancer: The Role of FGFR Inhibitors
Szklener, K., Chmiel, P., Michalski, A., & Mańdziuk, S. (2022) · Cancers · doi:10.3390/cancers14061416 · Cited by 22
Design and Rationale for a Phase II, Randomized, Open-Label, Two-Cohort Multicenter Interventional Study of Osimertinib with or Without Savolitinib in De Novo MET Aberrant, EGFR-Mutant Patients with Advanced Non-Small-Cell Lung Cancer: The FLOWERS Trial
Li, A., Chen, H., & Yang, J. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.09.009 · Cited by 19
Targeting MET Amplification: Opportunities and Obstacles in Therapeutic Approaches
Kumaki, Y., Oda, G., & Ikeda, S. (2023) · Cancers · doi:10.3390/cancers15184552 · Cited by 20
The search for improved systemic therapy of non-small cell lung cancer—What are today's options?
Früh, M. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.02.020 · Cited by 20
Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients
Martin, P., Shiau, C. J., Pasic, M. D., Tsao, M., Kamel‐Reid, S., Lin, S., Tudor, R., Cheng, S. Y.-S., Higgins, B. P., Burkes, R. L., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.22 · Cited by 19
Non–Small Cell Lung Cancer as a Precision Oncology Paradigm: Emerging Targets and Tumor Mutational Burden (TMB)
Tafe, L. J. (2019) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000244 · Cited by 19
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR -mutant lung cancer
Eser, P. Ö., Paranal, R. M., Son, J., Ivanova, E. V., Kuang, Y., Haikala, H. M., To, C., Okoro, J. J., Dholakia, K. H., Choi, J., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb3738 · Cited by 19
Met Receptor Acts Uniquely for Survival and Morphogenesis of EGFR-Dependent Normal Mammary Epithelial and Cancer Cells
Accornero, P., Miretti, S., Bersani, F., Quaglino, E., Martignani, E., & Baratta, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044982 · Cited by 21
Inositol Trisphosphate Receptor Type 3-mediated Enhancement of EGFR and MET Cotargeting Efficacy in Non–Small Cell Lung Cancer Detected by 18F-fluorothymidine
Iommelli, F., Rosa, V. D., Terlizzi, C., Monti, M., Panico, M., Fonti, R., & Vecchio, S. D. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3657 · Cited by 19
Relevance of Circulating Tumor Cells as Predictive Markers for Cancer Incidence and Relapse
Chelakkot, C., Yang, H., & Shin, Y. K. (2022) · Pharmaceuticals · doi:10.3390/ph15010075 · Cited by 19
MET inhibition in lung cancer.
Menis, J., Levra, M. G., & Novello, S. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2012.12.04 · Cited by 17
Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
Re, M. D., Vasile, E., Falcone, A., Danesi, R., & Petrini, I. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2014.908120 · Cited by 18
Expression of MET and SOX2 genes in non-small cell lung carcinoma with EGFR mutation
Cai, Y. (2011) · Oncology Reports · doi:10.3892/or.2011.1349 · Cited by 18
Incomplete target neutralization by the anti-cancer antibody rilotumumab
Greenall, S. A., Adams, T. E., & Johns, T. G. (2016) · mAbs · doi:10.1080/19420862.2015.1122149 · Cited by 18
c-MET overexpression as a prognostic biomarker in colorectal adenocarcinoma.
Abou-Bakr, A. A.-E., & Elbasmi, A. (2013) · PubMed · Cited by 18
Long range personalized cancer treatment strategies incorporating evolutionary dynamics
Yeang, C., & Beckman, R. A. (2016) · Biology Direct · doi:10.1186/s13062-016-0153-2 · Cited by 18
MET Amplification (MET/CEP7 Ratio ≥ 1.8) Is an Independent Poor Prognostic Marker in Patients With Treatment-naive Non–Small-cell Lung Cancer
Yin, W. H., Cheng, J., Tang, Z., Törüner, G., Hu, S., Guo, M., Robinson, M. K., Medeiros, L. J., & Tang, G. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.11.002 · Cited by 18
Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway
Wu, H., Fan, F., Liu, Z., Shen, C., Wang, A., & Lu, Y. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2792-x · Cited by 18
Lesion-Directed Therapies and Monitoring Tumor Evolution Using Liquid BiopsiesPreprint
Russo, M., & Bardelli, A. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a029587 · Cited by 20
Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient with Treatment Refractory Metastatic Colorectal Cancer
Jia, J., Morse, M. A., Nagy, R. J., Lanman, R. B., & Strickler, J. H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00305 · Cited by 17
Research progress on the role of bypass activation mechanisms in resistance to tyrosine kinase inhibitors in non-small cell lung cancer
Jiang, Z., Gu, Z., Yu, X.-M., Cheng, T., & Liu, B. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1447678 · Cited by 22
ARID1A serves as a receivable biomarker for the resistance to EGFR-TKIs in non-small cell lung cancer
Sun, D., Teng, F., Xing, P., & Li, J. (2021) · Molecular Medicine · doi:10.1186/s10020-021-00400-5 · Cited by 17
The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differences
Fogli, S., Tabbò, F., Capuano, A., Re, M. D., Passiglia, F., Cucchiara, F., Scavone, C., Gori, V., Novello, S., Schmidinger, M., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103602 · Cited by 17
L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab
Marrocco, I., Giri, S., Nieves, A. S., Gupta, N., Rudnitsky, A., Haga, Y., Romaniello, D., Sekar, A., Zerbib, M., Oren, R., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101142 · Cited by 18
Design, synthesis, and biological evaluation of 4-(2-fluorophenoxy)-7-methoxyquinazoline derivatives as dual EGFR/c-Met inhibitors for the treatment of NSCLC
Tang, S., Sun, C., He, X., Gan, W., Wang, L., Qiao, D., Guan, X., Xu, S., Zheng, P., & Zhu, W. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115939 · Cited by 17
Whole tumor analysis reveals early origin of the TERT promoter mutation and intercellular heterogeneity in TERT expression
Appin, C., Hong, C., Suwala, A. K., Hilz, S., Mathur, R., Solomon, D. A., Smirnov, I. V., Stevers, N. O., Shai, A., Wang, A., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad231 · Cited by 19
Small Molecule Therapeutics in the Pipeline Targeting for Triple-Negative Breast Cancer: Origin, Challenges, Opportunities, and Mechanisms of Action
James, N., Owusu, E., Rivera, G., & Bandyopadhyay, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116285 · Cited by 19
Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: Sensitivity and resistance
Takeuchi, S., & Yano, S. (2014) · Respiratory Investigation · doi:10.1016/j.resinv.2014.10.002 · Cited by 17
Using functional genomics to overcome therapeutic resistance in hematological malignancies
Calderon, F. A., Gregory, M. A., & DeGregori, J. V. (2012) · Immunologic Research · doi:10.1007/s12026-012-8353-z · Cited by 18
244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells
Zhang, Y., Yao, K., Shi, C., Jiang, Y., Liu, K., Zhao, S., Chen, H., Reddy, K., Zhang, C., Chang, X., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6236 · Cited by 17
MET Amplification and Response to MET Inhibitors in Stage IV Lung Adenocarcinoma
Suryavanshi, M., Shah, A., Kumar, D., Panigrahi, M. K., Metha, A., & Batra, U. (2017) · Oncology Research and Treatment · doi:10.1159/000457801 · Cited by 17
Inhibition of heat shock protein 90 destabilizes receptor tyrosine kinase ROR1 in lung adenocarcinoma
Khaledian, B., Taguchi, A., Shin‐ya, K., Kondo‐Ida, L., Kagaya, N., Suzuki, M., Kajino, T., Yamaguchi, T., Shimada, Y., & Takahashi, T. (2020) · Cancer Science · doi:10.1111/cas.14786 · Cited by 17
MET Suppresses Epithelial VEGFR2 via Intracrine VEGF-induced Endoplasmic Reticulum-associated Degradation
Chen, T. T., Filvaroff, E. H., Peng, J., Marsters, S. A., Jubb, A. M., Koeppen, H., Merchant, M. A., & Ashkenazi, A. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.03.021 · Cited by 17
The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines
Nam, H.-J., Kim, H.-P., Yoon, Y., Song, S. H., Min, A.-R., Han, S., Im, S., Kim, T. Y., Oh, D. Y., & Bang, Y. J. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9782-6 · Cited by 17
Quantitative imaging for development of companion diagnostics to drugs targeting HGF/MET
Huang, F., Ma, Z., Pollan, S. G., Yuan, X., Swartwood, S., Gertych, A., Rodriguez, M., Mallick, J., Bhele, S., Guindi, M. M., et al. (2016) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.49 · Cited by 17
Emerging Options for the Management of Non-Small Cell Lung Cancer
Binder, D., & Hegenbarth, K. (2013) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s10269 · Cited by 17
Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance
Attarian, S., Rahman, N., & Halmos, B. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.07.18 · Cited by 17
MET-targeted therapies for the treatment of non-small-cell lung cancer: A systematic review and meta-analysis
Xu, L., Wang, F., & Luo, F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1013299 · Cited by 16
The development of amivantamab for the treatment of non-small cell lung cancer
Brazel, D., & Nagasaka, M. (2023) · Respiratory Research · doi:10.1186/s12931-023-02558-4 · Cited by 19
SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma
Theard, P. L., Linke, A. J., Sealover, N. E., Daley, B. R., Yang, J. J., Cox, K., & Kortum, R. L. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13564 · Cited by 17
Development and Characteristics of Preclinical Experimental Models for the Research of Rare Neuroendocrine Bladder Cancer
Höfner, T., Macher‐Goeppinger, S., Klein, C., Rigo‐Watermeier, T., Eisen, C., Pahernik, S. A., Hohenfellner, M., Trumpp, A., & Sprick, M. R. (2013) · The Journal of Urology · doi:10.1016/j.juro.2013.06.053 · Cited by 16
From the Bench to Bedside: Biological and Methodology Considerations for the Future of Companion Diagnostics in Nonsmall Cell Lung Cancer
Dimou, A., Harrington, K. J., & Syrigos, K. (2011) · Pathology Research International · doi:10.4061/2011/312346 · Cited by 16
Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Mutation: First Line Treatment and Beyond
Rocco, D., Battiloro, C., Gravara, L. D., & Gridelli, C. (2018) · Reviews on Recent Clinical Trials · doi:10.2174/1574887114666181205155211 · Cited by 16
A novel combination treatment of antiADAM17 antibody and erlotinib to overcome acquired drug resistance in non-small cell lung cancer through the FOXO3a/FOXM1 axis
Li, J., Chen, P., Wu, Q., Guo, L., Leong, K. W., Chan, K. I., & Kwok, H. F. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04647-x · Cited by 16
Posttranslational modifications of FOXO1 regulate epidermal growth factor receptor tyrosine kinase inhibitor resistance for non-small cell lung cancer cells
Xu, Z., Shun, W.-W., Hang, J., Gao, B., & Hu, J. (2015) · Tumor Biology · doi:10.1007/s13277-015-3215-7 · Cited by 16
Applications of Innovation Technologies for Personalized Cancer Medicine: Stem Cells and Gene-Editing Tools
Hasanzadeh, A., Ebadati, A., Dastanpour, L., Aref, A. R., Zangabad, P. S., Kalbasi, A., Dai, X., Mehta, G., Ghasemi, A., Fatahi, Y., et al. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00102 · Cited by 16
Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial
Arrieta, O. G., Cruz‐Rico, G., Soto‐Pérez‐de‐Celis, E., Ramírez-Tirado, L.-A., Caballé‐Perez, E., Martínez-Hernández, J.-N., Martinez-Alvarez, I., Soca‐Chafre, G., Macedo-Pérez, E. O., & la Vega, H. A. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0425-x · Cited by 15
Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine
Pool, M., de Boer, H. R., Hooge, M. N. L., van Vugt, M. A. T. M., & de Vries, E. G. E. (2017) · Theranostics · doi:10.7150/thno.17934 · Cited by 15
β-catenin/TCF activity regulates IGF-1R tyrosine kinase inhibitor sensitivity in colon cancer
Lee, H., Kim, N., Yoo, Y. J., Kim, H.-J., Jeong, E., Choi, S., Moon, S. U., Oh, S. H., Mills, G. B., Yoon, S., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0362-5 · Cited by 15
Spatial EGFR Dynamics and Metastatic Phenotypes Modulated by Upregulated EphB2 and Src Pathways in Advanced Prostate Cancer
Liu, Y., Horning, A. M., Lieberman, B., Kim, M., Lin, C.-K., Hung, C., Chou, C., Wang, C., Lin, C.-L., Kirma, N. B., et al. (2019) · Cancers · doi:10.3390/cancers11121910 · Cited by 15
Targeting MET amplification in EGFR-mutant non-small-cell lung cancer
Rosell, R., CHAIB-OUKADOUR, I., & Santarpía, M. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30171-5 · Cited by 15
Comparison of Resistance Spectra after First and Second Line Osimertinib Treatment Detected by Liquid Biopsy
Jóri, B., Schatz, S., Kaller, L., Kah, B., Roeper, J., Ramdani, H., Diehl, L., Hoffknecht, P., Grohé, C., Griesinger, F., et al. (2021) · Cancers · doi:10.3390/cancers13122861 · Cited by 17
LXR ligands induce apoptosis of EGFR-TKI-resistant human lung cancer cells inï¿½vitro by inhibiting Akt-NF-κB activation
Liu, S., Cao, H., Chen, D., Yu, S., Sha, H., Wu, J., Ma, R., Wang, Z., Jing, C., Zhang, J., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.8182 · Cited by 15
Potential predictive value of serum targeted metabolites and concurrently mutated genes for EGFR-TKI therapeutic efficacy in lung adenocarcinoma patients with EGFR sensitizing mutations.
Han, X., Luo, R., Wang, L., Zhang, L., Wang, T., Zhao, Y., Xiao, S., Qiao, N., Xu, C., Ding, L., et al. (2020) · PubMed Central · Cited by 15
B3GNT3 as a prognostic biomarker and correlation with immune cell infiltration in lung adenocarcinoma
Wu, Y., Luo, J., Li, H., Huang, Y., Zhu, Y., & Chen, Q. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-493 · Cited by 14
Self-citation

Authors: Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., Lindeman, N. I., Murphy, C., Akhavanfard, S., Yeap, B. Y., Xiao, Y., Capelletti, M., Iafrate, A. J., Lee, C., Christensen, J. G., Engelman, J. A., & Jänne, P. A.
Affiliations: Harvard University (US)
Dana-Farber Cancer Institute (US)
Guangdong General Hospital (CN)
Massachusetts General Hospital (US)
Chinese University of Hong Kong (HK)
Brigham and Women's Hospital (US)
Pfizer (United States) (US)
Corresponding author: Engelman, Jeffrey A.
ORCID: Wu, Yi-Long
Song, Youngchul
Dias-Santagata, Dora
Toschi, Luca
Mok, Tony
Sequist, Lecia
Lindeman, Neal I.
Akhavanfard, Sara
Yeap, Beow Y.
Capelletti, Marzia
Iafrate, A. John
Lee, Charles
Christensen, James G.
Engelman, Jeffrey A.
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2010-01
Volume: 17
Issue: 1
Pages: 77-88
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccr.2009.11.022
PMC: PMC2980857
OpenAlex: W1985264867
Cited by: 1,059
References: 37
Citations by year: 2026: 22 · 2025: 31 · 2024: 36 · 2023: 58 · 2022: 41 · 2021: 55 · 2020: 41 · 2019: 56 · 2018: 66 · 2017: 73 · 2016: 93 · 2015: 84 · 2014: 88 · 2013: 94 · 2012: 106
FWCI: 83.75
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 1293 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Guangdong Provincial Hospital of Traditional Chinese Medicine
University of Hong Kong
Chinese University of Hong Kong
National Institutes of Health
National Cancer Institute (P50CA127003, R01CA140594, R01CA114465, P50CA090578, R01CA135257, K08CA120060, R01CA137008)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: MET amplification, EGFR mutation, non-small cell lung cancer, hepatocyte growth factor, clonal selection, combination therapy
MeSH terms: Animals, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Gene Amplification, Humans, Lung Neoplasms, Mutation, Proto-Oncogene Proteins, Signal Transduction, Gene Expression, Polymerase Chain Reaction, Hepatocyte Growth Factor, In Situ Hybridization, Fluorescence, Receptors, Growth Factor, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Quinazolinones, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks